Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study
Authors:
- 1 November 2018
- journal article
- letter
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 25 (6) , e767-e768
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerAnnals of Oncology, 2016